MARKSANS

Marksans Pharma Share Price

₹226.05 -6.64 (-2.85%)

22 Feb, 2025 23:27

SIP TrendupStart SIP in MARKSANS

Start SIP

Performance

  • Low
  • ₹224
  • High
  • ₹237
  • 52 Week Low
  • ₹130
  • 52 Week High
  • ₹359
  • Open Price₹233
  • Previous Close₹233
  • Volume953,414

Investment Returns

  • Over 1 Month -12.77%
  • Over 3 Month -26.88%
  • Over 6 Month + 2.85%
  • Over 1 Year + 44.76%
SIP Lightning

Smart Investing Starts Here Start SIP with Marksans Pharma for Steady Growth!

Invest Now

Marksans Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 27.8
  • PEG Ratio
  • 1.7
  • Market Cap Cr
  • 10,244
  • P/B Ratio
  • 4.5
  • Average True Range
  • 14.47
  • EPS
  • 8.13
  • Dividend Yield
  • 0.3
  • MACD Signal
  • -7.75
  • RSI
  • 37.41
  • MFI
  • 40.4

Marksans Pharma Financials

Marksans Pharma Technicals

EMA & SMA

Current Price
₹226.05
-6.64 (-2.85%)
pointer
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 16
  • 20 Day
  • ₹246.03
  • 50 Day
  • ₹262.01
  • 100 Day
  • ₹266.28
  • 200 Day
  • ₹246.02

Resistance and Support

229.05 Pivot Speed
  • R3 246.30
  • R2 241.55
  • R1 233.80
  • S1 221.30
  • S2 216.55
  • S3 208.80

What's your outlook on Marksans Pharma?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Marksans Pharma Ltd. is a global pharmaceutical company engaged in the research, development, and manufacturing of generic drugs. It offers a wide range of pharmaceutical formulations, serving key therapeutic areas such as pain management, cardiovascular, and gastrointestinal.

Marksans Pharma has an operating revenue of Rs. 2,474.40 Cr. on a trailing 12-month basis. An annual revenue growth of 17% is outstanding, Pre-tax margin of 19% is great, ROE of 15% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 82 which is a GOOD score indicating consistency in earnings, a RS Rating of 74 which is FAIR indicating the recent price performance, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 67 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Marksans Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-11 Quarterly Results
2024-11-12 Quarterly Results
2024-08-13 Quarterly Results
2024-05-30 Audited Results & Final Dividend
2024-02-13 Quarterly Results
Date Purpose Remarks
2024-09-17 FINAL Rs.0.60 per share(60%)Final Dividend
2023-06-07 FINAL Rs.0.50 per share(50%)Final Dividend

Marksans Pharma F&O

Marksans Pharma Shareholding Pattern

43.87%
3.15%
11.07%
0%
26.24%
15.67%

About Marksans Pharma

  • NSE Symbol
  • MARKSANS
  • BSE Symbol
  • 524404
  • Chairman & Managing Director
  • Mr. Mark Saldanha
  • ISIN
  • INE750C01026

Similar Stocks to Marksans Pharma

Marksans Pharma FAQs

Marksans Pharma share price is ₹226 As on 22 February, 2025 | 23:13

The Market Cap of Marksans Pharma is ₹10243.8 Cr As on 22 February, 2025 | 23:13

The P/E ratio of Marksans Pharma is 27.8 As on 22 February, 2025 | 23:13

The PB ratio of Marksans Pharma is 4.5 As on 22 February, 2025 | 23:13

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23